Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSET: Adjuvant Sunitinib in Resectable Esophageal Cancer
NCT00400114Phase 2Completed
- Sponsor
- University Health Network
- Start
- Sep 2006
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib in esophageal cancer, sponsored by University Health Network. Primary endpoint: Feasibility and efficacy of adjuvant sunitinib therapy at 5 years. Started Sep 2006; status: completed.
02
Drugs
sunitinib
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT00400114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00400114.